Clinical Trial Update: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brentuximab vedotin in relapsed/refractory CD30-positive non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED